ERAS and breast carcinoma: Synthesized compound antiproliferative activity and selectivity index against hormone-dependent MCF-7, hormone-independent MDA-MB-231 breast cancer cell lines, normal MRC-5 human lung tissue fibroblasts cell lines, and Ishikawa endometrial adenocarcinoma cell lines, as well as the downregulation of ERα in MCF-7 and PR antagonism in MCF-7 cell lines.